US11278599 — High concentration alpha-glucosidase compositions for the treatment of Pompe disease
Method of Use · Assigned to Amicus Therapeutics Inc · Expires 2033-03-07 · 7y remaining
What this patent protects
This patent protects compositions of high-concentration acid alpha-glucosidase with an active site-specific chaperone for treating Pompe disease.
USPTO Abstract
The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation.
Drugs covered by this patent
- Zavesca (MIGLUSTAT) · AstraZeneca
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3726 |
— | Zavesca |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.